Key Details
Last Dividend
$0.11Annual ROE
-84.48%Beta
-Events Calendar
Next earnings date:
N/ARecent quarterly earnings:
May 09, 2023Recent annual earnings:
Feb 28, 2022Next ex-dividend date:
N/ARecent ex-dividend date:
Apr 11, 2023Next split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
13 Oct '22 Piper Sandler
Neutral02 Aug '22 HC Wainwright & Co.
Neutral21 Apr '22 Oppenheimer
Outperform23 Feb '21 HC Wainwright & Co.
Buy07 July '20 HC Wainwright & Co.
Buy16 June '20 Cantor Fitzgerald
Overweight24 Dec '19 Oppenheimer
Outperform29 Aug '19 HC Wainwright & Co.
Buy29 Aug '19 H.C. Wainwright
Buy15 Nov '18 Cantor Fitzgerald
OverweightScreeners with OTIC included
No data
Market Data
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Dividend
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Profitability
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Efficiency
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Valuation
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Liquidity
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Cash Flow
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Institutional Ownership
Similar stocks
FAQ
- What is the primary business of Otonomy?
- What is the ticker symbol for Otonomy?
- Does Otonomy pay dividends?
- What sector is Otonomy in?
- What industry is Otonomy in?
- What country is Otonomy based in?
- When did Otonomy go public?
- Is Otonomy in the S&P 500?
- Is Otonomy in the NASDAQ 100?
- Is Otonomy in the Dow Jones?
- When was Otonomy's last earnings report?
- When does Otonomy report earnings?
- Should I buy Otonomy stock now?
What is the primary business of Otonomy?
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
What is the ticker symbol for Otonomy?
The ticker symbol for Otonomy is NASDAQ:OTIC
Does Otonomy pay dividends?
No, Otonomy does not pay dividends
What sector is Otonomy in?
Otonomy is in the Healthcare sector
What industry is Otonomy in?
Otonomy is in the Biotechnology industry
What country is Otonomy based in?
Otonomy is headquartered in United States
When did Otonomy go public?
Otonomy's initial public offering (IPO) was on 13 August 2014
Is Otonomy in the S&P 500?
No, Otonomy is not included in the S&P 500 index
Is Otonomy in the NASDAQ 100?
No, Otonomy is not included in the NASDAQ 100 index
Is Otonomy in the Dow Jones?
No, Otonomy is not included in the Dow Jones index
When was Otonomy's last earnings report?
Otonomy's most recent earnings report was on 9 May 2023
When does Otonomy report earnings?
The date for Otonomy's next earnings report has not been announced yet
Should I buy Otonomy stock now?
As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions